Driving clinical & biomedical research for recognition, diagnosis and treatment of ME/CFS.
The UK ME/CFS Biobank (UKMEB) is the first ME/CFS-specific biobank in Europe, and one of the first in the world. It has collected over 30,000 aliquots of blood from patients with ME/CFS and multiple sclerosis (as well as healthy controls), using a rigorous and consistent set of scientific protocols.
The UKMEB is committed to patient participation, and ensures that its research is always informed by and for the benefit of people with ME/CFS. It is led by a steering group that includes patient and charity representatives, and has already contributed to highly significant research in immunology (including on NK and T cells and cytokine profiles), genetics, virology, clinical medicine, epidemiology and on the disabling effects of ME/CFS.
The UK ME/CFS Biobank is run by the CureME research team at the London School of Hygiene and Tropical Medicine and is overseen by a Steering Committee comprising of patient/carer representatives, academics and charity stakeholders.
People suffer from ME/CFS
ME/CFS female to male ratio
More people suffer from ME/CFS than MS
Myalgic Encephalomyelitis (ME) is a long-term (chronic), fluctuating, neurological condition that causes symptoms affecting many body systems, more commonly the nervous and immune systems. ME affects an estimated 250,000 people in the UK, and around 17 million people worldwide. People with ME/CFS experience severe, persistent fatigue associated with post-exertional malaise, the body’s inability to recover after expending even small amounts of energy, and the disease has as a result also been referred to as Chronic Fatigue Syndrome.